Rather, at present, the favored interpretation is that, it is a quantitative deviation of normal neuronal parameters in schizophrenia, probably arising at least partly during development,

and putatively affecting functional connectivity between various brain regions. These hypotheses are elaborated further below. However, it is important to remain critical of Inhibitors,research,lifescience,medical the empirical data, which could equally lead to the conclusion that, though brain structure is clearly altered in schizophrenia, its location, nature, and consequences remain largely unknown.53 Neurochemistry of EGFR phosphorylation schizophrenia A wide range of neurochemical parameters have been investigated in schizophrenia, both postmortem54,55 and in vivo.56,57 Among a multitude of findings, four major neurochemical systems have been most Inhibitors,research,lifescience,medical implicated: dopamine, serotonin (5-HT), glutamate, and γ-aminobutyric acid (GABA). Dopamine The dopamine hypothesis of schizophrenia has been ncurochemically preeminent, for 40 years.58,59

It received support from various postmortem findings of increased dopamine content and higher densities of dopamine D2 receptors in schizophrenia.60 However, despite its longevity, there is still no consensus as to precisely what the dopamine hypothesis explains, nor the nature of the supposed abnormality. Inhibitors,research,lifescience,medical There are two main difficulties. First, antipsychotics have effects of their own on dopaminergic parameters (eg, receptor densities), confounding studies of medicated subjects. Second, molecular biology has revealed a large and complex dopamine receptor family, increasing the Inhibitors,research,lifescience,medical potential sites and mechanisms of dysfunction. Increased D2 receptor densities occur in patients with schizophrenia, but it is unclear what, proportion, if any, is not attributable to antipsychotic medication.61 Statistical methods have been used to argue that there is a schizophrenia-associated elevation, but this must be balanced against positron emission tomography

(PET) studies of D2 receptors in drug-naive and first-episode cases, all but one of which are negative. Recently, it has been suggested that the “clustering” Inhibitors,research,lifescience,medical of D2 receptors is altered in schizophrenia, with more of the receptors existing as monomers rather than oligomers.62 This situation has two implications: it complicates interpretation unless of the imaging data, since different, ligands have differential selectivity for these receptor states; and it means that there could be alterations in the functional activity of D2 receptors even without an increase in total receptor number (eg, via G protein coupling). Expression of D1 and D3 receptors has also been reported to be changed in schizophrenia in postmortem or in vivo studies, but these reports are either unconfirmed or contradicted by other studies.63 Particular controversy has surrounded the D4 receptor following a report, that it was upregulated several-fold in schizophrenia.